simendan has been researched along with transforming growth factor beta in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akhtar, MS; Dhyani, N; Hassan, MQ; Ismail, MV; Najmi, AK; Pillai, KK | 1 |
1 other study(ies) available for simendan and transforming growth factor beta
| Article | Year |
|---|---|
Levosimendan reduces myocardial damage and improves cardiodynamics in streptozotocin induced diabetic cardiomyopathy via SERCA2a/NCX1 pathway.
Topics: Animals; Body Weight; Cardiomyopathies; Cardiotonic Agents; Diabetes Mellitus, Experimental; Heart; Hemodynamics; Hydrazones; Male; Natriuretic Peptide, Brain; Nitric Oxide; Pyridazines; Rats; Rats, Wistar; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Sodium-Calcium Exchanger; Streptozocin; Transforming Growth Factor beta; Troponin I | 2016 |